Video

Dr. Rampal on Unmet Needs in Myelofibrosis and Polycythemia Vera

Raajit K. Rampal, MD, PhD, discusses unmet needs in the treatment of patients with myelofibrosis and polycythemia vera.

Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses unmet needs in the treatment of patients with myelofibrosis and polycythemia vera.

In 2011, the JAK1/2 inhibitor ruxolitinib (Jakafi) became the first approved agent designed to treat patients with myelofibrosis. In 2014, ruxolitinib became the first drug to receive regulatory approval for the treatment of patients with polycythemia vera. In August 2019, fedratinib (Inrebic), a JAK2 inhibitor, was approved for the treatment of patients with intermediate-2 or high-risk primary or secondary myelofibrosis.

Beyond these agents, there are few options that are available to patients, explains Rampal. About half of patients with myelofibrosis who are treated with ruxolitinib will progress within 1.5 to 3 years. Similarly, response rates could decrease over time for patients with polycythemia vera who are treated with ruxolitinib.

Therefore, clinical trials should be considered for patients with either myelofibrosis or polycythemia vera who progress on these agents, concludes Rampal.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing [email protected], or by calling 833-315-2722.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity